This is a preview of subscription content, log in via an institution to check access.
Reference
Zeng X, et al. Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma. Advances in Therapy : 26 Mar 2021. Available from: URL: http://doi.org/10.1007/s12325-021-01699-6
Rights and permissions
About this article
Cite this article
Adding daratumumab to standard care in newly diagnosed multiple myeloma: more life-years at high cost. PharmacoEcon Outcomes News 876, 2 (2021). https://doi.org/10.1007/s40274-021-7616-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7616-0